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Background: Acquired resistance to Tamoxifen remains a critical problem in breast cancer patient treatment, yet
the underlying causes of resistance have not been fully elucidated. Abberations in the Wnt signalling pathway have
been linked to many human cancers, including breast cancer, and appear to be associated with more metastatic
and aggressive types of cancer. Here, our aim was to investigate if this key pathway was involved in acquired
Tamoxifen resistance, and could be targeted therapeutically.
Methods: An in vitro model of acquired Tamoxifen resistance (named TamR) was generated by growing the
estrogen receptor alpha (ER) positive MCF7 breast cancer cell line in increasing concentrations of Tamoxifen
(up to 5 uM). Alterations in the Wnt signalling pathway and epithelial to mesenchymal transition (EMT) in response
to Tamoxifen and treatment with the Wnt inhibitor, IWP-2 were measured via quantitative RT-PCR (qPCR) and TOP/
FOP Wnt reporter assays. Resistance to Tamoxifen, and effects of IWP-2 treatment were determined by MTT
proliferation assays.
Results: TamR cells exhibited increased Wnt signalling as measured via the TOP/FOP Wnt luciferase reporter assays.
Genes associated with both the β-catenin dependent (AXIN2, MYC, CSNK1A1) and independent arms (ROR2, JUN),
as well as general Wnt secretion (PORCN) of the Wnt signalling pathway were upregulated in the TamR cells
compared to the parental MCF7 cell line. Treatment of the TamR cell line with human recombinant Wnt3a (rWnt3a)
further increased the resistance of both MCF7 and TamR cells to the anti-proliferative effects of Tamoxifen
treatment. TamR cells demonstrated increased expression of EMT markers (VIM, TWIST1, SNAI2) and decreased
CDH1, which may contribute to their resistance to Tamoxifen. Treatment with the Wnt inhibitor, IWP-2 inhibited cell
proliferation and markers of EMT.
Conclusions: These data support the role of the Wnt signalling pathway in acquired resistance to Tamoxifen.
Further research into the mechanism by which activated Wnt signalling inhibits the effects of Tamoxifen should be
undertaken. As a number of small molecules targeting the Wnt pathway are currently in pre-clinical development,
combinatorial treatment with endocrine agents and Wnt pathway inhibitors may be a useful therapeutic option in
the future for a subset of breast cancer patients.
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Among several advances that have contributed to the
decreased mortality from breast cancer observed in the
past two decades, the routine use of adjuvant endocrine
therapies directed at the estrogen receptor (ER) pathway
is a major contributor. Tamoxifen, a selective estrogen
receptor modulator (SERM) that blocks mammary estro-
gen action at its receptor, increases patient survival fol-
lowing a diagnosis of ER positive breast cancer [1-3].
The long-term benefit of Tamoxifen, however, is limited
by the development of acquired resistance. A recent
meta-analysis of adjuvant Tamoxifen for 5-years revealed
a 33% distant tumour relapse rate within 8-years post
treatment [4,5]. Endocrine relapse predicts a poor clin-
ical outcome as about 40% of these woman have wide-
spread disease at the time of clinical presentation. One
pathway which has been identified as of potential im-
portance in acquisition of drug resistance to Tamoxifen,
is the Wnt signalling pathway [6].
The Wnt signalling pathway is an important deve-
lopmental pathway, that is frequently dysregulated in
human cancers, including breast cancer [6-10]. Wnt sig-
nalling is important for cell migration, invasion, ad-
hesion and survival. Wnt ligands primarily signal via
membrane bound Frizzled receptors through a number
of different but interconnected signalling pathways, in-
cluding the Wnt/Ca2+, β-catenin and planar-cell polarity
pathways [11-13]. In general, the Wnt pathway is divided
into the canonical/ β-catenin dependent pathway and
the non canonical/ β-catenin independent pathways
(including the planar cell polarity pathway and Wnt/
Ca2+ pathway), though it is now understood that there is
significant overlap and cross-talk between the individual
pathways.
As a consequence of the frequent involvement of
the Wnt signalling pathway in multiple cancers, many
attempts have been made to target the pathway thera-
peutically [14]. In general, these attempts have had
somewhat limited success, likely due to the complexity
of the Wnt network and the fact that many of these in-
hibitors were targeted further downstream in the path-
way. The Wnt inhbitor IWP-2 was recently identified as
a small molecule inhibitor of Porcupine, thus capable of
inhibiting secretion and activity of all Wnt ligands and
downstream pathways [15].
Wnt signalling has also recently been linked to the
process of epithelial to mesenchymal transition (EMT)
[16-18]. This is unsurprising due to the Wnt pathways’
well established and defined links to cell polarity, differ-
entiation and cell migration. EMT is a crucial step that
cancer cells undergo in order to invade and metastasise
[19]. Cells that have undergone an EMT possess simi-
liarities to cancer stem cells in their plasticity, loss of
adherence and capacity for migration and invasion. Ingeneral, the hallmarks of a cancer cell which has under-
gone EMT is a loss of E-cadherin expression, and gain
of Vimentin [20]. The transcription factors Twist and
Snail are frequently upregulated in parallel. Another
important similarity is with cancer stem cells, in that
cells which have undergone an EMT have been shown
to more chemoresistant in a number of different tumour
types treated with different cancer therapies [21,22].
In this present study we sought to profile the mRNA
expression of key Wnt signalling pathway and EMT as-
sociated genes in an in vitro model of acquired Tamoxi-
fen resistant breast cancer (TamR). The TamR cell line
was developed to simulate the occurrence of acquired
Tamoxifen resistance in clinical practice. To further sub-
stantiate the correlation between aberrant Wnt signal-
ling and acquired Tamoxifen resistant breast cancer, we
also investigated the effects of modulating Wnt signal-
ling pathway activity via recombinant Wnt proteins and
the Wnt inhibitor, IWP-2 in this model cell line.
Methods
Cell culture
The human breast adenocarcinoma cell line MCF7
was obtained from American Type Culture Collection
(Manassas, VA, USA), and maintained in Dulbecco’s
Modified Eagles Medium (DMEM) (Gibco, Carlsbad,
CA, USA). TamR cells were selected from the MCF7
parental cell line grown in graduated concentrations
(0.1 μM to 5.0 μM) of 4-hydroxy-Tamoxifen (Sigma
Aldrich, Castle Hill, NSW, Australia) over six months.
The final concentration of 5 μM was chosen to simulate
the pharmacological dosages prescribed to patients, as
described previously [23]. TamR cells were maintained
in 5 μM of Tamoxifen and DMEM prepared without
phenol red indicator. All media contained 5% charcoal
stripped foetal bovine serum (Sigma Aldrich), 5% glu-
tamate and 100 units penicillin, 100 μg/mL streptomy-
cin. All cells were grown in a humidified atmosphere of
5% CO2, at 37°C and were demonstrated to be free of
mycoplasma contamination.
RNA extraction and cDNA synthesis
RNA was extracted using the RNeasy mini kit (Qiagen,
Valencia, CA, USA) following manufacturer’s instruc-
tions. Final concentrations were determined using the
Nanodrop DA-1000 Spectrophotometer. Only samples
with an absorbance of 260/280 nm at a ratio bet-
ween 2.0 and 2.1 were used for cDNA synthesis. 1 μg of
RNA was purified from genomic DNA using DNase I
(Invitrogen, Carlsbad, CA, USA) and reverse transcribed
to cDNA using the QuantiTectW Reverse Transcription
Kit (Qiagen) as per manufacturer’s instructions. To veri-
fy that the cDNA synthesized was free of genomic DNA
contamination, an additional control reaction devoid of
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each purified RNA sample. The resulting cDNA product
was then used as a template for PCR amplification.
Quantitative RT-PCR (qPCR)
A 25 μl qPCR consisting of 25 ng diluted cDNA,
QuantiFastW Sybr Green Dye (Qiagen) and 0.1 μM of
each qPCR primer pair was performed to obtain quanti-
fiable expressions of Wnt and EMT-related gene targets
in MCF7 and TamR cells. All qPCR was conducted in
a Stratagene MxPro™3005P. Each sample was re-
peated in triplicate and normalized against the three
housekeeping genes SDHA (Succinate dehydrogenase
complex subunit A), HSPCB (Heat shock 90kD pro-
tein 1, beta) and YWHAZ (Tyrosine 3-monooxygenase
/tryptophan 5-monooxygenase activation protein, zeta
polypeptide). The mRNA expressions of the genes of
interest were standardized against the geometric mean of
the three control genes using the Vandesompele normal-
isation method [22]. The expression values of TamR cells
relative to that of MCF7 cells and expressed as fold-
change. All experiments contained a “no amplicon” nega-
tive control. Primer sequences were as follows (50 to 30):
ER forward (F) CCACCAACCAGTGCACCATT, ER re-
verse (R) GGTCTTTTCGTATCCCACCTTTC, HER2 F
GGGAAGAATGGGGTCGTCAAA, HER2 R CTCCTCC
CTGGGGTGTCAAGT, Axin2 F TGTCTTAAAGGTCT
TGAGGGTTGAC, Axin2 R CAACAGATCATCCCATC
CAACA, CCNDD1 F GGCGGAGGAGAACAAACAGA,
CCND1 R TGGCACAAGAGGCAACGA, ROR2 F CGA
CTGCGAATCCAGGACC, ROR2 RGGCAGAACCCAT
CCTCGTG, CDH1 F AGGCCAAGCAGCAGTACATT,
CDH1 R ATTCACATCCAGCACATCCA, VIM F CCA
AACTTTTCCTCCCTGAACC, VIM R GTGATGCTGA
GAAGTTTCGTTGA, TWIST1 F GCCAATCAGCCAC
TGAAAGG, TWIST1 R TGTTCTTATAGTTCCTCTG
ATTGTTACCA, SDHA F TGGGAACAAGAGGGCATC
TG, SDHA R CCACCACTGCGCGGTTCTTG, HSPCB
FAAGAGAGCAAGGCAAAGTTTGAG, HSPCB R TGG
TCACAATGCAGCAAGGT, YWHZA F ACTTTTGGTA
CATTGTGGCTTCAA, YWHZA R CCGCCAGGACAA
ACCAGTAT.
RT2 Profiler PCR array
The Human Wnt Signalling Pathway (PAHS-043, Qiagen)
and our own custom designed (CAPH-10800), Qiagen)
RT2 Profiler PCR Arrays were utilized to investigate a
panel of 84 Wnt specific and 84 EMT related genes in
TamR and MCF7 cells as per manufacturer’s instructions.
Briefly, 500 ng of RNA was converted to cDNA using RT2
First Strand Kit (Qiagen). The resultant cDNA product
was immediately amplified by qPCR using RT2 SYBR
Green qPCR Master Mix (Qiagen), using a Stratagene
MxPro™3005P. The Ct values (threshold cycle) forboth cell lines were evaluated using the provided web-
based portal (http://pcrdataanalysis.sabiosciences.com/pcr/
arrayanalysis.php) and normalised to five housekeeping
genes. This analysed data comprised of fold-regulations,
which represents the normalized gene expression in the
TamR cells compared against the normalized gene ex-
pression in the MCF7 cells. Our criteria for a signifi-
cant differential expression was set at a greater or less
than 2.5-fold regulation in TamR cells when com-
pared against MCF7 cells.
Proliferation assay
Cell proliferation was measured via MTT Cell Prolifera-
tion Kit I (Roche, Basel, Switzerland) following the man-
ufacturer’s instructions. Briefly, TamR and MCF7 cells
were seeded into a 96-well plate with a concentration of
4000 cells per well, then either left unstimulated or stim-
ulated with 0.1 μg/ml recombinant Wnt3a (rWnt3a,
R&D Systems) for 48 hours. Cells were then treated with
5 μM of Tamoxifen (Sigma) or 50% Dimethyl sulfoxide
(DMSO) (Sigma) for the final 24 hours. All cells were
then labelled with MTT ((3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide), incubated in a humi-
dified atmosphere of 5% CO2, at 37°C for 4 hours and
absorbance measured on a microplate reader (SpectraMax
M2). The raw absorbance was subsequently measured in
10 replicates at 572 nm, readouts averaged and adjusted
accordingly.
All cell numbers were determined using the CountessW
Automated Cell Counter (Invitrogen) and further verified
via manual cell counting with an aid of a haemocytometer
to ensure accurate seeding of cells.
Wnt reporter assay
MCF7 and TamR cells were plated at a concentration of
5000 cells/well on white bottomed 96 well plates. Cells
were serum starved overnight and co-transfected with
0.2 μg of either TOPflash (2 sets of 3 copies (the second
set in the reverse orientation) of the TCF binding site)
or FOPflash (2 full and one incomplete copy of the
TCF binding site (mutated) followed by 3 copies in
the reverse orientation) expression plasmids (Millipore,
Temecula, CA, USA), and 0.1 μg pRL-TK (Renilla-
TK-luciferase vector, Promega) as a control, using
Lipofectamine2000. Cells were subsequently treated with
recombinant Wnt3a (rWnt3a 0.1 μg/ml) for 48 hours
prior to luciferase activities being measured using a
Glomax 96 Microplate Luminometer (Turner Biosys-
tems Instrument, Sunnyvale, CA, USA). Firefly luciferase
activity was normalized for transfection efficiency by
dividing by the Renilla luciferase activity. The TOP/FOP
ratio was used as a measure of β-catenin driven tran-
scription. Average activity and standard deviations were
derived from octopulate transfected samples.
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The data represented in the results section are presented
as means with error bars representing standard deviation
(SD). The two-tailed unpaired t-test was used to deter-
mine the significance. The following symbols were used
to denote statistical significance * P < 0.05, ** P < 0.01,
*** P <0.001.Results
TamR cells are resistant to tamoxifen
TamR cells appeared larger in size and flatter, than
the parental MCF7 cell line (Figure 1a). They were
less likely to form large aggregates of cells, and ap-
peared less adherent than MCF7 cells (Figure 1a).
MTT proliferation assays were used to confirm that
the laboratory developed model cell line was indeed
resistant to the anti-proliferative effects of Tamoxifen
(Figure 1b). TamR cells exhibited statistically signi-
ficant resistance to the Tamoxifen at concentrations
ranging from 5 μM to 13.5 μM, well above the clin-
ical dose [23]. Many previous studies have noted that
acquired resistance to Tamoxifen is often accompanied by
an increased expression of Her2, and a decreased expres-
sion of ERα [24,25], which we confirmed in our TamR
cells using qPCR (Figure 1c).Figure 1 TamR cells are resistant to Tamoxifen. a: TamR cells
were larger, flatter and exhibited a more mesenchymal phenotype
than the parental cell line MCF7. 10X magnification. b: MTT
proliferation assays were performed on parental MCF7 cells and
TamR cells treated with increasing doses of Tamoxifen(0.0–15.0 μM)
over 24 hours. 50% DMSO was used as a control as it is known to
eliminate cells independent of ER status. TamR cells were
successfully selected for acquired Tamoxifen resistance from its
parental cell line MCF7 as they continued to proliferate in Tamoxifen
concentrations, 5 μM, 7.5 μM, 10 μM, 11.5 μM and 13.5 μM, that
eliminate MCF7 cells. Graph represents the average cell proliferation
in percentage of 10 replicates with standard deviation represented
by error bars. *** P<0.001. Abbreviation: Dimethyl sulfoxide (DMSO).
c: mRNA expression of ER and HER2 was measured using qPCR.
Graph represents the mRNA fold-regulation values of TamR cells
relative to MCF7 cells, normalized against three housekeeping genes
with standard deviation of triplicate experiments represented by
error bars** P<0.01. Abbreviations: Estrogen receptor alpha (ER),
Human Epidermal Growth Factor Receptor 2 (HER2).TamR cells exhibit increased Wnt signalling
In addition, TamR cells showed increased expression of
the direct Wnt target gene, Axin2 and the non-canonical
Wnt receptor Ror2 while exposed to Tamoxifen (Figure 2a).
CyclinD1 (CCND1) expression was significantly de-
creased in TamR cells compared with the parental cell
line, MCF7 (Figure 2a). The Wnt RT Profiler PCR
array further indentified a number of canonical and
non-canonical Wnt genes whose transcription was sig-
nificantly increased (greater than 4 fold) in the TamR cell
line. These were DKK1, JUN, PORCN, CSNK1A1 and
MYC (Figure 2b).
This apparent transcriptional upregulation of the ca-
nonical (β-catenin dependent) Wnt pathway was con-
firmed using the the well established TOPflash/FOPflash
Wnt reporter assay. Stimulation with human recombin-
ant Wnt3a (rWnt3a) had no effect on MCF7 cells, but
significantly increased the transcription of the Wnt lucif-
erase reporter in the TamR cells (Figure 2c). Next, we
tested the effect of rWnt3a treatment on cell prolifera-
tion and Tamoxifen resistance. Treatment with rWnt3a
and 5 μM Tamoxifen inhibited the proliferation of both
the MCF7 and TamR cells compared to treatment with
Tamoxifen alone. Furthermore, rWnt3a treatment in the
TamR cells enhanced their resistance to Tamoxifen back
to near basal levels (Figure 2d).TamR cells have increased expression of EMT markers
Because the TamR cells displayed some morphological
differences from the parental MCF7 cells, as well as
the emerging links between Wnt signalling and EMT,
we conducted further expression profiling which con-
firmed TamR cells express some of the hallmarks of
EMT. Compared to their parental cell line MCF7,
TamR cells exhibited significantly decreased expres-
sion of E-cadherin (CDH1) and significantly increased
Figure 2 TamR cells exhibit increased Wnt signalling. a: mRNA expression of Wnt-related genes was measured using qPCR. Graph represents
the mRNA fold-regulation values of TamR cells relative to MCF7 cells, normalized against three housekeeping genes with standard deviation (s.d)
of triplicate experiments represented by error bars. *P<0.05, ** P<0.01. b: mRNA expression changes of Wnt target genes were measured using RT
Profiler PCR arrays and normalised to five housekeeping genes. Criteria for significant change include a statistically significant validation
determined by the manufacturer and fold regulation of greater or less than 4. c: MCF7 and TamR cells were co-transfected with pRL-TK (Renilla)
and either TOPflash or FOPflash expression plasmids. Cells were subsequently treated with 0.1 μg/ml recombinant Wnt3a (rWnt3a) for 24 hours
prior to luciferase activities being measured using a Glomax 96 Microplate Luminometer. Average activity and s.ds were derived from octopulate
transfected samples. Results represent the average of 3 experiments and bars represent the s.d of the mean. ***P<0.001. d: MTT proliferation
assays were performed on parental MCF7 cells and TamR cells treated with 5 μM Tamoxifen and 0.1 μg/ml recombinant Wnt3a (rWnt3a) for
24 hours. 50% DMSO was used as a control. Treatment with rWnt3a and 5 μM Tamoxifen inhibited the proliferation of both the MCF7 and TamR
cells compared to treatment with Tamoxifen alone. rWnt3a treatment in the TamR cells enhanced their resistance to Tamoxifen back to near
basal levels. Graph represents the average cell proliferation in percentage of 10 replicates with s.d represented by error bars. *P<0.05, *** P<0.001.
e: mRNA expression of EMT markers was measured using qPCR. Graph represents the mRNA fold-regulation values of TamR cells relative to MCF7
cells, normalized against three housekeeping genes with s.d of five independent experiments represented by error bars. **P<0.01, ***P<0.001*.
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Slug (SNAI2) showed a modest non significant increase in
expression, and Twist (TWIST1) showed a slight decrease
in expression.
The Wnt inhibitor, IWP-2, inhibits cell proliferation and
EMT
We first confirmed that the Wnt inhbitor, IWP-2, was
effective in our cell line by treating TamR cells with
5 μM IWP-2 and determining the effects on TCF/LEFmediated transcription, as measured by a TOPflash/
FOPflash Wnt reporter assay. IWP-2 significantly inhi-
bited Wnt signalling in the TamR cell line (Figure 3a).
To determine if inhibition of Wnt signalling would alter
the proliferation of TamR cells and sensitivity to Tam-
oxifen, we treated cells with increasing concentrations of
Tamoxifen in the presence or absence of IWP-2. Treat-
ment with IWP-2 alone significantly reduced prolifera-
tion by approximately 20% (Figure 3b). At Tamoxifen
concentrations of 5–11.5 μM, the addition of IWP-2
Figure 3 The Wnt inhibitor IWP-2 inhibits proliferation and EMT in TamR cells. a: TamR cells were pre-treated with 5 μM IWP-2 for 24 hours
prior to co-transfection with pRL-TK (Renilla) and either TOPflash or FOPflash expression plasmids. Cells were subsequently treated with 5 μM
IWP-2 for 24 hours prior to luciferase activities being measured using a Glomax 96 Microplate Luminometer. Average activity and standard
deviations were derived from triplicate transfected samples. Results represent the average of 4 experiments and bars represent the standard deviation
(s.d) of the mean. **P<0.01. b: MTT proliferation assays were performed on TamR cells treated with increasing doses of Tamoxifen(0.0–15.0 μM) over
24 hours, with or without the addition of 5 μM IWP-2. The graph represents the average cell proliferation of triplicate wells in three independent
experiments, with standard deviation represented by error bars. ** P<0.01. c: mRNA expression of EMT markers was measured using qPCR in TamR
cells treated for 48 hours with 5 μM IWP-2. Graph represents the mRNA fold-regulation values of control cells relative to IWP-2 treated cells,
normalized against three housekeeping genes. This is a single experiment, and error bars represent the standard deviation of triplicate wells.
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statistically significant) providing some support for fu-
ture research into combination therapy targeting ER and
Wnt signalling (Figure 3b). In addition, IWP-2 treatment
resulted in decreased expression of the key EMT tran-
scription factors, Vimentin and Twist (Figure 3b).
Discussion
Despite the development of aromatase inhibitors and
therapies targeting other key proteins involved in breast
carcinogenesis, Tamoxifen remains in widespread clinical
use. However, both de novo and acquired resistance to
Tamoxifen occur frequently in the clinical management
of breast cancer patients. Understanding the mecha-
nisms behind resistance will be important for not onlyimproving treatment success, but in understanding the
key signalling pathways involved in breast carcinogenesis.
At present, research has considered relatively few sig-
nalling pathways and translation of these works to the
clinical setting has proved to be insufficient in restoring
Tamoxifen sensitivity [26]. There is an imperative need
to identify previously unconsidered mechanisms for suc-
cessful modulation of therapeutic response in this ag-
gressive subtype of breast cancer.
In this study, we considered the Wnt signalling path-
way as a potential mechanism involved in acquired
Tamoxifen resistant breast cancer. This was based on
substantial evidence in the literature implicating aber-
rant activation of Wnt signalling in aggressive breast
tumour subtypes including triple negative breast cancers,
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oxifen [7,9,10]. Here, we have extended this association
to include acquired Tamoxifen resistant cells by pro-
viding data that largely indicate increased activation of
both canonical and non-canonical Wnt pathways in our
TamR cells.
AXIN2, MYC, DKK1 and CCND1 are well-documen-
ted downstream canonical Wnt-target genes that re-
gulate cell proliferation, metastasis and tumourigenesis
[27-30]. Our data, which revealed a upregulation of
AXIN2, DKK1 and MYC in the TamR cells, are largely
consistent with findings documented in current litera-
ture on triple negative breast cancer [7,31-36]. In par-
ticular, a review by Bouchalova et al. (2009) classified
MYC amplifications as the most frequent aberrations in
triple negative breast cancer [32]. Additionally, AXIN2,
the most reliable endogenous gene target of Wnt ca-
nonical pathway [28] activation was markedly upregu-
lated upon mRNA analysis of high-grade breast tumours
[7,27]. Our study showed a trend to increased expression
of AXIN2, though this was not statistically significant.
Interestingly, our findings for CCND1 showed a two
fold downregulation in the TamR cells compared to that
of MCF7 cells. This differs from our findings on other
Wnt target genes as well as some evidence in current lit-
erature. Elevated expression of CCND1 was commonly
associated with a more aggressive breast disease pheno-
type and an adverse patient outcome [37]. A reason for
this discrepancy could be due to the lack of specificity of
CCND1 as a downstream Wnt signalling gene target
[28,38]. It has been shown that a wide variety of mito-
genic signalling pathways in addition to the Wnt path-
way converge at the level of CCND1 mRNA and/or
protein up-regulation [38]. Furthermore, a number of
studies have disputed whether CCND1 is indeed a ca-
nonical Wnt target gene at all [39,40]. Despite this, our
combined results of the three up-regulated Wnt gene
targets and increased Wnt reporter gene activity are in-
dicative of canonical Wnt pathway activation in TamR
cells. However, while DKK1 is identified as a down-
stream target of canonical Wnt signalling, this is sus-
pected to be as part of a negative feedback loop as
DKK1 is an inhibitor of the canonical co-receptor LRP
[29]. Therefore it is possible that the upregulation of the
canonical Wnt pathway is tempered somewhat by the in-
creased expression of DKK1. The increase in expression
of CK1alpha (CSNK1A1), a critical regulator of the APC
destruction complex [41] supports the activation of the
canonical Wnt pathway in response to Tamoxifen [42].
Furthermore, stimulation of TamR cells with rWnt3a
protein potentiated Tamoxifen resistance in TamR cells.
Collectively, this data adds to the increasing body of evi-
dence implicating the increased activation of canonical
pathway with aggressive subtypes of breast cancer.A strong increase in expression of Porcupine (PORCN)
was also noted, which is essential for secretion of all Wnt
ligands from the endoplasmic reticulum. This suggested
that the increase in Wnt signalling may be network-wide
and not specific to a particular arm of the pathway.
Interestingly genes involved in the β-catenin indepen-
dent or non-canonical Wnt pathways appear to also be
upregulated following acquired Tamoxifen resistance.
Expression of both the downstream non-canonical Wnt
target gene JUN and the recently identified Wnt5a
receptor, ROR2 were also increased in TamR cells.
These data suggest an upregulation of the entire Wnt
signalling network which should be further explored,
particularly in light of recent studies identifying the
importance of ROR2 driven signalling in human can-
cer [43]. The addition of the Wnt inhibitor, IWP-2
which should target both arms of the Wnt pathway,
appeared to further enhance the anti-proliferative ef-
fects of Tamoxifen in this model of acquired Tamoxi-
fen resistance.
TamR cells also exhibited altered transcription of a
number of key genes involved in EMT. This shift to a
more mesenchymal phenotype fits with the current lit-
erature suggesting that drug treatment can effect cellular
behaviour and plasticity, with EMT linked to chemo-
resistance in a number of cell lines and tumour types,
including breast cancer [22,44-46].Conclusions
In conclusion, this study provides insight into the role
of Wnt signalling pathway in acquired Tamoxifen re-
sistant breast cancer. Combined, our data suggest that
acquisition of resistance to Tamoxifen is accompanied
by an increase in the Wnt signalling pathway and a
transition to a more mesenchymal phenotype. Future
research should therefore consider members of this
pathway as one of the potential targets to be used in
combination therapy for successful restoration of ac-
quired Tamoxifen sensitivity. This raises the possibil-
ity that drugs targeting the Wnt signalling pathway,
many of which are already in development, could be
added to the arsenal of drugs for individualised and
targeted treatment in breast cancer.Abbreviations
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